Table 3.

Adverse drug reactions in CLL studies Hx-CD20–402 and Hx-CD20–406

Adverse drug reactions are listed by MedDRA body system organ class and by frequency as very common (≥1 in 10), common (≥1 in 100 to <1 in 10), uncommon (≥1 in 1,000 to <1 in 100), rare (≥1 in 10,000 to <1 in 1,000), very rare (<1 in 10,000), and not known (cannot be estimated from available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Abbreviations: CLL, chronic lymphocytic leukemia; MedDRA, Medical Dictionary for Regulatory Activities.